FDA Inspection 1220409 — Amgen, Inc.

Amgen, Inc. — FEI 2026154

The FDA completed an inspection of Amgen, Inc. on Sep 14, 2023 in Thousand Oaks, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Sep 14, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Thousand Oaks, CA (United States)

Additional Details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.